A Study of Acetyl Hexapeptide-8 (AH8) in Treatment of Blepharospasm
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00942851|
Recruitment Status : Completed
First Posted : July 21, 2009
Results First Posted : September 6, 2012
Last Update Posted : September 6, 2012
- Blepharospasm is caused by excessive contraction of the muscles that close the eye. It can be treated with injections of botulinum neurotoxin (BoNT), which works by weakening those muscles.
- Acetyl Hexapeptide-8 (AH-8) is the active ingredient in a number of cosmetic creams used to treat wrinkles, and is marketed under the trade name Argireline(Copyright). Like BoNT, AH-8 works to weaken the muscles, but is available as a skin cream instead of an injection. AH-8 has never been used to treat people with blepharospasm.
- To determine if AH-8 can be used as part of a treatment regimen for blepharospasm.
- Individuals 18 years of age and older who have blepharospasm and have been receiving successful treatment with botulinum toxin injections.
- Participants will be involved in the study for a maximum of 7 months.
- Patients will have a complete physical and neurological exam, and will be asked questions about their blepharospasm. Patients will then receive BoNT injections in the same areas of the muscle around the eye and at the same doses that have been effective previously.
- After the injections, patients will receive a container of either the active cream (with AH-8) or cream without AH-8, and will be instructed on how to apply it.
- Patients will return 1 month after the first visit for another neurologic exam and questions, and will be asked about any side effects. Another supply of cream will be given.
- Five additional visits will take place on a monthly basis, and patients will be given additional supplies of the cream as needed. Patients will stop participating in the study if they require another BoNT injection for blepharospasm. The study will end after 7 months.
|Condition or disease||Intervention/treatment||Phase|
|Focal Dystonia||Drug: Acetyl-Hexapeptide Topical Treatment Drug: placebo||Phase 1 Phase 2|
To study the efficacy of cutaneous application of Acetyl Hexapeptide-8 (AH8) in the therapy of blepharospasm.
22 patients with blepharospasm.
This will be a double blind, placebo-controlled trial. Patients receiving treatment of blepharospasm with botulinum neurotoxin (BoNT) will be recruited. They will receive either the study substance or a placebo cream containing the emulsion but no active substance, in twice daily applications to the eyelids beginning the day following a BoNT injection treatment. They will continue to apply the cream and we will record the time until their condition worsens back to baseline following benefit from the injections, hypothesizing that the cream application will prolong the time until the need for the next injection by at least 3 months.
Primary: time until the Jankovic Blepharospasm Rating Scale (JBRS) reverts back to baseline.
Secondary: Change in the JBRS at 6 months; Change in the JBRS at 7 months if not receiving BoNT; Change in the JBRS at 3 months; Change in the Blepharospasm Disability Scale at 6 months
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||24 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Investigator, Outcomes Assessor)|
|Official Title:||A Study of Acetyl Hexapeptide-8 (AH8) in Treatment of Blepharospasm|
|Study Start Date :||July 2009|
|Actual Primary Completion Date :||October 2010|
|Actual Study Completion Date :||October 2010|
AH-8 containing topical intervention
Drug: Acetyl-Hexapeptide Topical Treatment
AH-8 containing topical treatment
Placebo Comparator: placebo
topical intervention WITHOUT AH-8
topical treatment NOT containing AH-8
- Time Until Jankovic Blepharospasm Rating Scale (JBRS) Reverts Back to Baseline [ Time Frame: 3-7 months ]The JBRS is a severity scale for blepharospasm, ranging from 0 (no symptoms) to 8 (the most severe symptoms, functionally blind). It includes measures of blink frequency and severity of abnormal eye closure. The scale was measured at baseline (before intervention) and followed over time. Return to baseline value represents loss of benefit from BoNT injection. The time to return to baseline JBRS is an indication of added benefit from the topical intervention.
- Change in the JBRS at 3 Months [ Time Frame: baseline to 3 months ]The JBRS is a severity scale for blepharospasm, ranging from 0 (no symptoms) to 8 (the most severe symptoms, functionally blind). It includes measures of blink frequency and severity of abnormal eye closure. The scale was measured at baseline (before intervention) and followed over time.
- % Blepharospasm Disability Scale (BDS) Change at 3 Months [ Time Frame: baseline to 3 months ]% BDS change at 3 months. The BDS is a quality of life scale ranging from 0 (no symptoms) to 26 (maximum impact of symptoms on quality of life). The questions are specific for impairment related to blepharospasm. We compared the percentage change over three months in the active and placebo arms.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00942851
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike|
|Bethesda, Maryland, United States, 20892|